Home » GSK, Valeant Submit NDA for Epilepsy Drug
GSK, Valeant Submit NDA for Epilepsy Drug
GlaxoSmithKline (GSK) and Valeant Pharmaceuticals International
have filed an NDA for their epilepsy treatment retigabine with the FDA and a marketing authorization application with the European Medicines Agency. Retigabine
is intended as an adjunctive therapy to treat adult epilepsy patients with partial-onset seizures, the companies say in a statement last week.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May